Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx Group (MDXG) Asset Writedowns and Impairment: 2016-2025

Historic Asset Writedowns and Impairment for Mimedx Group (MDXG) over the last 8 years, with Sep 2025 value amounting to $2.1 million.

  • Mimedx Group's Asset Writedowns and Impairment rose 836.92% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year increase of 322.89%. This contributed to the annual value of $595,000 for FY2024, which is 58.94% down from last year.
  • Per Mimedx Group's latest filing, its Asset Writedowns and Impairment stood at $2.1 million for Q3 2025, which was up 485.75% from $351,000 recorded in Q2 2025.
  • Mimedx Group's 5-year Asset Writedowns and Impairment high stood at $2.2 million for Q2 2022, and its period low was -$279,000 during Q3 2024.
  • Moreover, its 3-year median value for Asset Writedowns and Impairment was $351,000 (2025), whereas its average is $471,909.
  • Per our database at Business Quant, Mimedx Group's Asset Writedowns and Impairment skyrocketed by 23,633.33% in 2023 and then tumbled by 162.42% in 2024.
  • Mimedx Group's Asset Writedowns and Impairment (Quarterly) stood at $100,000 in 2021, then tumbled by 97.00% to $3,000 in 2022, then spiked by 23,633.33% to $712,000 in 2023, then tumbled by 36.24% to $454,000 in 2024, then soared by 836.92% to $2.1 million in 2025.
  • Its last three reported values are $2.1 million in Q3 2025, $351,000 for Q2 2025, and $742,000 during Q1 2025.